-continued

```
<211> LENGTH: 321
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      polynucleotide

<400> SEQUENCE: 29

gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag     60

aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat ctccgtggag    120

tgggagagca atgggcagcc ggagaacaac tacaagacca cacctcccat gctggactcc    180

gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg    240

aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc    300

ctctccctgt ctccgggtaa a                                              321


<210> SEQ ID NO 30
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> SEQUENCE: 30

atgcatgagg ctctgcacaa ccactacaca cagaagagcc tctccctgtc tccgggcaaa     60


<210> SEQ ID NO 31
<211> LENGTH: 213
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      polynucleotide

<400> SEQUENCE: 31

atctccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacacctccc     60

atgctggact ccgacggctc cttcttcctc tacagcaagc tcaccgtgga caagagcagg    120

tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac    180

acgcagaaga gcctctccct gtctccgggc aaa                                 213
```

The invention claimed is:

1. A nucleic acid encoding the amino acid sequence of the C-terminal part of the C_H3-domain of an immunoglobulin of the class IgA or IgG, or the amino acid sequence of the C-terminal part of the C_H4-domain of an immunoglobulin of the class IgE or IgM, wherein the glycine-lysine-dipeptide comprised in said amino acid sequence of the C-terminal part of the C_H3- or C_H4-domain is encoded by one of the following nucleic acid sequences, ggaaca, ggcaac, gggaaa, ggaaag, ggcaag, and gggaag, the nucleic acid ggaaaa, or the nucleic acid ggcaaa.

2. The nucleic acid of claim **1**, wherein said nucleic acid encodes an amino acid sequence selected from the amino acid sequences of SEQ ID NO: 1, 3, 4, 5, 6, 7, or 8.

3. The nucleic acid of claim **2**, wherein the nucleic acid encoding said glycine-lysine-dipeptide is preceded by the nucleotide g or a.

4. The nucleic acid of claim **3**, wherein said glycine-lysine-dipeptide is encoded by the nucleic acid ggaaaa, or the nucleic acid ggcaaa, or the nucleic acid gggaaa.

5. The nucleic acid of claim **1**, wherein the C-terminal part of the C_H3 domain, or the C-terminal part of the C_H4 domain, comprises at least the 20 C-terminal amino acids of the immunoglobulin heavy chain primary amino acid sequence.

6. The nucleic acid of claim **1**, wherein said nucleic acid encodes a part of the C-terminal constant domain of an immunoglobulin heavy chain of the class IgA, IgE, IgM, or IgG and is selected from the nucleic acids of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 30, or 31.

7. The nucleic acid of claim **6**, wherein said nucleic acid is selected from the nucleic acids of SEQ ID NO: 17, 18, 19, 22, 23, 30, or 31.

8. The nucleic acid of claim **7**, wherein nucleic acid is selected from the nucleic acids of SEQ ID NO: 17, 18, 19, 22, or 23.

9. The nucleic acid of claim **6**, wherein said nucleic acid encodes a part of the C-terminal constant domain of a human immunoglobulin heavy chain of the class IgG1 or IgG4.

10. A plasmid comprising the nucleic acid of claim **1**.

11. An isolated cell comprising the nucleic acid of claim **1**, wherein said cell is a mammalian cell.

12. The cell of claim **11**, characterized in that said mammalian cell is selected from a CHO cell, a HEK cell, or a BHK cell.